Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319731 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04319731 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 10 participants.
The verdict
NCT04319731, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.
Interventions
- BIOLOGICAL Human Amniotic Fluid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-03-20 |
| Est. Completion | 2020-06-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319731
The ClinicalTrials.gov registry entry for NCT04319731 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human Amniotic Fluid is the first listed.
NCT04319731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04319731 about?
NCT04319731 is a clinical study titled "A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure". The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and...
What is the current status of trial NCT04319731?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-03-20. Estimated completion is 2020-06-09.
What interventions are being tested in trial NCT04319731?
The interventions under investigation include: Human Amniotic Fluid (BIOLOGICAL).
Who is sponsoring clinical trial NCT04319731?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.